Atara Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2022 Annual Meeting of Stockholders held by Atara Biotherapeutics, Inc. on June 23, 2022. The filing details the outcomes of three specific matters submitted to a vote by security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results rather than financial performance.
Material Changes and Voting Results
The following matters were voted upon and approved by stockholders:
- Election of Directors: All three nominees were elected to serve until the 2025 annual meeting.
- Roy Baynes, M.D., Ph.D.: 63,131,166 For; 17,769,265 Withheld.
- Matthew K. Fust: 68,265,757 For; 12,634,674 Withheld.
- Ronald C. Renaud, Jr.: 69,029,789 For; 11,870,642 Withheld.
- Executive Compensation (Say-on-Pay): Stockholders approved the advisory vote on named executive officer compensation.
- For: 78,488,147
- Against: 2,362,933
- Abstain: 49,351
- Ratification of Auditors: Stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- For: 86,968,307
- Against: 35,221
- Abstentions: 72,848
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document references a definitive proxy statement filed on April 27, 2022, for more detailed descriptions of the matters voted upon.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to contextualize the voting percentages.
- Review the April 27, 2022 Proxy Statement for detailed executive compensation figures and director biographies.
- Confirm the specific terms of the engagement with Deloitte & Touche LLP for the 2022 fiscal year.
- Note that approximately 6.2 million broker non-votes were recorded for the director elections and executive compensation vote.